• Nenhum resultado encontrado

J. bras. pneumol. vol.42 número5

N/A
N/A
Protected

Academic year: 2018

Share "J. bras. pneumol. vol.42 número5"

Copied!
9
0
0

Texto

Loading

Imagem

Figure 1. Hierarchical theoretical model of prognostic factors and death from lung cancer.
Table 1. Distribution and 60-month disease-speciic survival probability of the study cohort of patients with non-small  cell lung cancer by clinical stage, as well as by distal factor and by intermediate factor of the proposed model
Table 2. Distribution and 60-month disease-speciic survival probability of the study cohort of patients with non-small  cell lung cancer by clinical stage and by proximal factor of the proposed model
Table 3. Results of the hierarchical Cox model of patients with stage I/II non-small cell lung cancer

Referências

Documentos relacionados

The aim of this study was to evaluate the frequency of epidermal growth factor receptor and KRAS mutations in a population of Brazilian patients with non-small cell lung

American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung

The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the

Objectives: To determine differences in overall survival and quality of life among patients with stage IV non-small cell lung cancer non-metastatic to the brain treated with

The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the

The objective of the present article was to analyze the importance of social, behavioral, and clinical factors on the survival time of patients with non-small cell lung cancer

With this device, we investigated the effects of epidermal growth factor (EGF) and matrix metalloproteinase (MMP) inhibitor, GM6001 on invadopodia formation by human non-small cell

Quantification of Cell-Free mSHOX2 Plasma DNA for Therapy Monitoring in Advanced Stage Non-Small Cell (NSCLC) and Small-Cell Lung Cancer (SCLC) Patients.. Bernd Schmidt 1 , Julia